A partnership between contract development and manufacturing organization (CDMO) Almac Group and Amicus Therapeutics has resulted in the European approval of Amicus’ first orphan drug product and precision medicine Galafold (migalastat, also referred to as AT1001). Galafold was approved as a first line therapy for long-term treatment of adults and adolescents—aged 16 years and older—with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. ...